BioUtah News
-
Owlet and Locus Health Partner to Seamlessly Deliver Infant Health Data into Remote Patient Monitoring Programs
This first-of-its-kind infant care collaboration for Owlet enables clinicians to access Owlet’s data through Locus Health’s platform, enhancing…
-
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test.
-
New Preclinical Study Demonstrates Feasibility of Microbubble-Mediated, Non-Thermal Focused Ultrasound for Brain Tumor Ablation
Salt Lake City, UT –Wednesday November, 5th 2025— Researchers from the University of Utah and Microvascular Therapeutics (MVT)…
-
Owlet Partners with Rhapsody to Connect Remote Baby Monitoring Data to EHRs
Collaboration bridges home and hospital, creating a secure pathway for pediatric insights to be managed and shared.
-
J3 Bioscience Announces Collaboration to Study LIV-Ring VR101 for Cancer-Therapy–Related Vaginal Dryness
Investigator-Initiated, grant-supported pilot study evaluating a novel non-prescription therapy for cancer-related vaginal dryness.
-
2025 BioUtah Life Sciences Awards Presented at the Mayer Brown Utah Life Sciences Summit
BioUtah will honor outstanding leaders in Utah’s life sciences community with five awards recognizing contributions to the industry.
-
PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial
PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial
-
Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
The target lesion primary patency (TLPP)1 and access circuit primary patency (ACPP)2 of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)…
-
Oxford Nanopore and bioMérieux launch AmPORE-TB, a Research Use Only sequencing-based solution to rapidly characterize drug resistant-tuberculosis
Oxford Nanopore and bioMérieux launch AmPORE-TB, a Research Use Only sequencing-based solution to rapidly characterize drug resistant-tuberculosis
-
Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform
Company forms new AI business unit, led by Chief Technology & AI Officer Christopher Thurston, to unify and…
-
Health Insurance Costs 2026: Steep Increases Ahead for Employers, Including Life Sciences
Health insurance costs are projected to rise sharply in 2026
-
Co-Diagnostics Forms New AI Business Unit and Expands Global Footprint with CoMira Diagnostics
Co-Diagnostics Forms New AI Business Unit and Expands Global Footprint with CoMira Diagnostics
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
